Peramivir and Sodium Chloride Injection.

Function and indication:
Used for influenza A or B. Used for the treatment of influenza A and B (peramivir can effectively treat influenza A and B, but there is not much clinical application data for influenza B). Patients should use it within 48 hours of the first onset of symptoms.
Usage and dosage:
This product has a variety of dosage forms and specifications. The same medicine produced by different manufacturers may have inconsistent instructions. Please read the drug instructions carefully before taking the medicine and follow the doctor’s instructions. Peramivir sodium chloride injection: 1. Intravenous drip. Start treatment within 48 hours of the onset of influenza symptoms. 2. Adults: The general dosage is 300 mg, a single intravenous drip, and the drip time is not less than 30 minutes. For patients with severe complications, 600 mg can be used, a single intravenous drip, and the drip time is not less than 40 minutes. For patients with severe symptoms, it can be administered once a day, and repeated for 1-5 days. In addition, the dosage can be reduced as appropriate according to age and symptoms. 3. Children: Under normal circumstances, peramivir can be used once a day, 10 mg/kg body weight each time, a single intravenous drip over 30 minutes. It can also be repeated daily according to the condition, not more than 5 days. The upper limit of a single dose is within 600 mg. 4. Precautions for use and dosage: (1) Start administration as soon as possible after the onset of influenza symptoms. There is no clinical efficacy data for starting administration 48 hours after the onset of symptoms. (2) For repeated administration, whether to continue administration should be determined based on clinical symptoms such as body temperature. Do not blindly continue administration. (3) For patients with renal insufficiency, due to the risk of continued increase in plasma drug concentration, the dosage must be adjusted according to the renal impairment. This drug is limited to intravenous infusion.
Adverse reactions:
According to foreign literature reports, among the 968 patients in clinical studies, 239 cases (24.7%) had adverse reactions including abnormal clinical test values. The main adverse reactions were diarrhea in 56 cases (5.8%), neutropenia in 27 cases (2.8%), and proteinuria in 24 cases (2.5%). Among the 117 patients in the safety evaluation test for young children, 34 cases (29.1%) had adverse reactions including abnormal clinical test values. The main manifestations were diarrhea in 12 cases (10.3%), neutropenia in 11 cases (9.4%), and vomiting in 6 cases (5.1%). Young children and minors may have abnormal behaviors and should be monitored. Serious adverse reactions: 1. Shock (frequency unknown): During the administration process, close observation should be made. If symptoms such as low blood pressure, pale face and cold sweat that may indicate shock occur, the administration should be stopped immediately and appropriate measures should be taken. 2. Leukopenia, neutropenia (1% to <5%): Because there may be leukopenia and neutropenia, close observation should be made. If there are abnormalities, the administration should be discontinued and appropriate disposal measures should be taken. 3. Serious adverse reactions of similar antiviral drugs: Because other anti-influenza virus drugs have serious adverse reactions, close observation should be made. If there are abnormalities, the administration should be discontinued and appropriate disposal measures should be taken. Other serious adverse reactions of similar antiviral drugs are as follows: (1) Allergy. (2) Pneumonia. (3) Fulminant hepatitis, liver damage, jaundice. (4) Mucocutaneous eye syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Toxic Epidermal Necrolysis: TEN). (5) Acute renal failure. (6) Thrombocytopenia. (7) Psychoneural symptoms (disordered consciousness, abnormal behavior, delirium, hallucinations, delusions, convulsions, etc.). (8) Hemorrhagic enteritis. For other adverse reactions, please refer to the drug instructions.
Contraindications:
This product is contraindicated in patients with a history of allergy to any other neuraminidase inhibitor (oseltamivir phosphate or zanamivir) or the components of peramivir injection.